<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Saf</journal-id><journal-id journal-id-type="iso-abbrev">Drug Saf</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Drug safety</journal-title></journal-title-group><issn pub-type="ppub">0114-5916</issn><issn pub-type="epub">1179-1942</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10363992</article-id><article-id pub-id-type="pmcid-ver">PMC10363992.1</article-id><article-id pub-id-type="pmcaid">10363992</article-id><article-id pub-id-type="pmcaiid">10363992</article-id><article-id pub-id-type="manuscript-id">NIHMS1915516</article-id><article-id pub-id-type="pmid">36642778</article-id><article-id pub-id-type="doi">10.1007/s40264-022-01267-z</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1915516</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1915516</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Comparative Safety Analysis of Opioid Agonist Treatment in Pregnant Women with Opioid Use Disorder: A population-based study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="S">Shuang</given-names></name><degrees>MPH</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Meador</surname><given-names initials="KJ">Kimford J</given-names></name><degrees>MD</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pawasauskas</surname><given-names initials="J">Jayne</given-names></name><degrees>PharmD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lewkowitz</surname><given-names initials="AK">Adam K</given-names></name><degrees>MD</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ward</surname><given-names initials="KE">Kristina E.</given-names></name><degrees>PharmD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Brothers</surname><given-names initials="TN">Todd N.</given-names></name><degrees>PharmD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hartzema</surname><given-names initials="A">Abraham</given-names></name><degrees>PhD</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Quilliam</surname><given-names initials="BJ">Brian J.</given-names></name><degrees>PhD</degrees><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wen</surname><given-names initials="X">Xuerong</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1"><label>1:</label>Pharmacy Practice, College of Pharmacy, University of Rhode Island</aff><aff id="A2"><label>2:</label>Department of Neurology, Stanford University</aff><aff id="A3"><label>3:</label>Maternal Fetal Medicine, Women and Infants Hospital of Rhode Island, Alpert Medical School of Brown University</aff><aff id="A4"><label>4:</label>Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida</aff><aff id="A5"><label>5:</label>College of Health Sciences, University of Rhode Island</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">Authors&#8217; contribution: Wang and Wen have full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p><p id="P2">Concept and design: Wen, Wang, Meador.</p><p id="P3">Acquisition, analysis, or interpretation of data: Wen, Wang.</p><p id="P4">Drafting of the manuscript: Wen, Wang, Meador.</p><p id="P5">Critical revision of the manuscript for important intellectual content: All authors.</p><p id="P6">Statistical analysis: Wang.</p><p id="P7">Clinical, technical, or material support: Pawasauskas, Lewkowitz, Ward, Brothers, Hartzema, Quilliam.</p><p id="P8">Supervision: Wen, Meador</p><p id="P9">All authors read and approved the final version.</p></fn><corresp id="CR1"><bold>Corresponding Author:</bold> Xuerong Wen, PhD, MPH, Associate Professor of Pharmacoepidemiology, Health Outcome, Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, <email>xuerongwen@uri.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>16</day><month>1</month><year>2023</year></pub-date><volume>46</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">441288</issue-id><fpage>257</fpage><lpage>271</lpage><pub-history><event event-type="nihms-submitted"><date><day>19</day><month>07</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>24</day><month>07</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>24</day><month>07</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 13:25:13.573"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1915516.pdf"/><abstract id="ABS1"><sec id="S1"><title>INTRODUCTION</title><p id="P10">Receipt of opioid agonist treatment (OAT) during early and late pregnancy for opioid use disorder (OUD) may relate to varying perinatal risks.</p></sec><sec id="S2"><title>METHODS</title><p id="P11">We conducted a retrospective cohort study of pregnant women with OUD to examine the effect of time-varying prenatal OAT exposure using buprenorphine or methadone on adverse neonatal and pregnancy outcomes, using Rhode Island Medicaid claims data and vital statistics during 2008-2016. Time-varying exposure was evaluated in early (0-20-weeks) and late (&#8805;21-weeks) pregnancy. Marginal structural models with inverse-probability-treatment-weighting were applied.</p></sec><sec id="S3"><title>RESULTS</title><p id="P12">Of 400 eligible pregnancies, 85 and 137 individuals received buprenorphine and methadone, respectively, during early pregnancy. Compared with 152 untreated OUD pregnancies, methadone exposure in both periods was associated with an increased risk of preterm birth (aOR: 2.52; 95%CI: 1.07-5.95), low birth weight (aOR: 2.99; 95%CI: 1.34-6.66), neonatal intensive care unit admission (aOR, 5.04; 95%CI: 2.49-10.21), neonatal abstinence syndrome (NAS; aOR: 11.36; 95%CI: 5.65-22.82), respiratory symptoms (aOR, 2.71; 95%CI: 1.17-6.24), and maternal hospital stay &gt;7 days (aOR, 14.51; 95%CI: 7.23-29.12). Similar patterns emerged for buprenorphine regarding NAS (aOR: 10.27; 95%CI: 4.91-21.47) and extended maternal hospital stay (aOR: 3.84; 95%CI: 1.83-8.07). However, differences were found favoring use of buprenorphine for preterm birth versus untreated pregnancies (aOR: 0.17; 95%CI: 0.04-0.77), and for several outcomes versus methadone.</p></sec><sec id="S4"><title>CONCLUSIONS</title><p id="P13">Methadone and buprenorphine prescribed for the treatment of OUD during pregnancy are associated with varying perinatal risks. However, buprenorphine may be preferred in the setting of pregnancy OAT. Further research is necessary to confirm our findings and minimize residual confounding.</p></sec></abstract><kwd-group><kwd>OAT</kwd><kwd>OUD</kwd><kwd>Methadone</kwd><kwd>Buprenorphine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>